Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Serum Institute...

    Serum Institute unveils new rotavirus vaccine Rotasiil-Liquid to prevent diarrhoea

    Farhat NasimWritten by Farhat Nasim Published On 2020-01-10T12:17:06+05:30  |  Updated On 10 Jan 2020 12:17 PM IST

    The new rotavirus vaccine, Rotasiil - Liquid can be directly administered in 2 ml dose orally, thus saving time as well as cold chain space. It can be stored at 2-8 degrees Celsius for up to 24 months, Serum Institute of India said in a statement.


    New Delhi: Vaccine major Serum Institute on Thursday said it has launched a new variant of its WHO prequalified rotavirus vaccine Rotasiil, called Rotasiil - Liquid.


    Available in a single dose tube, Rotasiil - Liquid can be directly administered in 2 ml dose orally, thus saving time as well as cold chain space. It can be stored at 2-8 degrees Celsius for up to 24 months, Serum Institute of India said in a statement.


    Rotavirus is a very contagious virus that causes diarrhoea.


    Also Read: Serum Institute to unveil thermostable rotavirus vaccine Rotasiil in 9 countries next year


    Rotasiil - Liquid will be available across domestic and international markets. The initial production aim of the vaccine is around 25-30 million doses per annum, which will be augmented to over 80 million doses per annum, it added.


    "The new launch will propel us towards improving the health of our children and reduce hospitalization and conditions related with diarrhoea such as malnutrition, delayed physical and mental development amongst children," Serum Institute of India (SII) CEO Adar Poonawalla said.


    As per the World Health Organization (WHO), an estimated 215,000 children under five years of age die each year from vaccine-preventable rotavirus infection globally, the statement said.


    In India, rotavirus diarrhoea is among the top ten causes of child morbidity and mortality in children, killing around 47,100 children under five years of age, it added.


    Also Read: IAVI Serum Institute to Develop Affordable Antibody Products for HIV

    diarrhoeamalnutritionpharmapharma companypharma newsROTASIILrotavirusSerum InstitutevaccineWHOWorld Health Organisation
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok